Comparison of Antibiotic Use and Bacterial Infections among Patients Hospitalized to the Intensive Care Unit During the First and Fifth Wave of COVID-19 Pandemic in a University Hospital in Iran

Document Type : Original Article(s)

Authors

1 Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

3 Amin Hospital, Isfahan University of Medical Sciences, Isfahan, Iran

4 Department of Biotechnology, Faculty of Biological Sciences, Falavarjan Branch, Islamic Azad University, Isfahan, Iran

5 Department of Bacteriology and Virology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

10.48305/jims.v43.i835.1328

Abstract

Background: The overuse of antibiotics during the COVID-19 pandemic has increased the risk of antimicrobial resistance, posing a serious challenge to healthcare systems. This study aimed to compare patterns of antibiotic consumption and microbial resistance among ICU-admitted COVID-19 patients during two different waves of the pandemic.
Methods: This descriptive cross-sectional study was conducted on COVID-19 patients admitted to the ICU during the first (2020) and fifth (2021) waves of the pandemic. Indicators such as mortality rate, number of microbial cultures, frequency of Gram-positive and Gram-negative bacteria, antibiotic consumption, and antibiotic resistance patterns in Gram-negative bacteria were evaluated.
Findings: During the first wave, 439 patients and during the fifth wave, 506 patients were admitted to the ICU. Positive bacterial infections were reported in 12.3% and 15.8% of patients, respectively, while mortality rates were 35% and 40.9%. Klebsiella pneumoniae was the most common organism in both waves, and the lowest resistance was observed to colistin. In the first wave, meropenem (3,316 vials) and vancomycin (1,937 vials) had the highest usage, whereas in the fifth wave, levofloxacin (1,745 vials) and meropenem (1,735 vials) were the most prescribed antibiotics.
Conclusion: In the fifth wave, the implementation of infection control programs and antimicrobial stewardship led to a reduction in antibiotic consumption and decreased drug resistance among Gram-negative bacteria. These findings highlight the importance of continuing such interventions in the management of ICU patients.

Highlights

Mohammad Shirzadi:  PubMed , Google Scholar

Keywords

Main Subjects

References

  1. Vâţă A, Roşu FM, Dorneanu OS, Lehaci AE, Luca Ş, Loghin, II, et al. Antibiotic Usage in the COVID-19 Intensive Care Unit of an Infectious Diseases Hospital from Nord-Eastern Romania. Medicina (Kaunas). 2023; 59(4): 645.
  2. de Macedo V, Santos GS, Silva RN, Couto CNM, Bastos C, Viecelli E, et al. Healthcare-associated infections: a threat to the survival of patients with COVID-19 in intensive care units. J Hosp Infect 2022; 126: 109-15.
  3. Vincent JL, Sakr Y, Singer M, Martin-Loeches I, Machado FR, Marshall JC, et al. Prevalence and Outcomes of Infection Among Patients in Intensive Care Units in 2017. JAMA 2020; 323(15): 1478-87.
  4. Akbari M, Dehghani Y, Shirzadi M, Pourajam S, Hosseinzadeh M, Sajadi M, et al. Bacterial infections and outcomes of inpatients with COVID-19 in the intensive care unit during the delta-dominant phase: the worst wave of pandemic in Iran. Front Public Health 2024; 12: 1411314.
  5. Ripa M, Galli L, Poli A, Oltolini C, Spagnuolo V, Mastrangelo A, et al. Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors. Clin Microbiol Infect 2021; 27(3): 451-7.
  6. Baghdadi JD, Coffey KC, Adediran T, Goodman KE, Pineles L, Magder LS, et al. Antibiotic Use and Bacterial Infection among Inpatients in the First Wave of COVID-19: a Retrospective Cohort Study of 64,691 Patients. Antimicrob Agents Chemother 2021; 65(11): e0134121.
  7. Garcia-Vidal C, Sanjuan G, Moreno-García E, Puerta-Alcalde P, Garcia-Pouton N, Chumbita M, et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect. 2021; 27(1): 83-8.
  8. Vijay S, Bansal N, Rao BK, Veeraraghavan B, Rodrigues C, Wattal C, et al. Secondary Infections in Hospitalized COVID-19 Patients: Indian Infect Drug Resist 2021; 14: 1893-903.
  9. Gudiol C, Durà-Miralles X, Aguilar-Company J, Hernández-Jiménez P, Martínez-Cutillas M, Fernandez-Avilés F, et al. Co-infections and superinfections complicating COVID-19 in cancer patients: A multicentre, international study. J Infect 2021; 83(3): 306-13.
  10. Micheli G, Sangiorgi F, Catania F, Chiuchiarelli M, Frondizi F, Taddei E, et al. The Hidden Cost of COVID-19: Focus on Antimicrobial Resistance in Bloodstream Infections. Microorganisms. 2023;11(5):1299.
  11. Gajic I, Jovicevic M, Popadic V, Trudic A, Kabic J, Kekic D, et al. The emergence of multi-drug-resistant bacteria causing healthcare-associated infections in COVID-19 patients: a retrospective multi-centre study. J Hosp Infect. 2023;137:1-7.
  12. Baiou A, Elbuzidi AA, Bakdach D, Zaqout A, Alarbi KM, Bintaher AA, et al. Clinical characteristics and risk factors for the isolation of multi-drug-resistant Gram-negative bacteria from critically ill patients with COVID-19. J Hosp Infect 2021; 110: 165-71.
  13. Pourajam S, Zafarbakhsh A, Hosseinzadeh M, Shirzadi M, Siavash M, Solgi H. Secondary bacterial infection caused by ST16 NDM-1 and OXA-48-producing colistin and carbapenem-resistant Klebsiella pneumoniae treated with tigecycline in a pregnant woman with COVID-19. J Pharm Policy Pract 2023; 16(1): 38.
  14. Khoshbakht R, Kabiri M, Neshani A, Khaksari MN, Sadrzadeh SM, Mousavi SM, et al. Assessment of antibiotic resistance changes during the Covid-19 pandemic in northeast of Iran during 2020–2022: an epidemiological study. Antimicrob Resist Infect Control 2022; 11(1): 121.
  15. Bardi T, Pintado V, Gomez-Rojo M, Escudero-Sanchez R, Azzam Lopez A, Diez-Remesal Y, et al. Nosocomial infections associated to COVID-19 in the intensive care unit: clinical characteristics and outcome. Eur J Clin Microbiol Infect Dis 2021; 40(3): 495-502.
  16. Rahman T, Islam MS, Paul S, Islam MM, Samadd MA, Reyda RN, et al. Prescription patterns in an intensive care unit of COVID-19 patients in Bangladesh: A cross-sectional study. Health Sci Rep 2023; 6(11): e1711.
  17. Avdeev S, Rachina S, Belkova Y, Kozlov R, Versporten A, Pauwels I, et al. Antimicrobial Prescribing Patterns in Patients with COVID-19 in Russian Multi-Field Hospitals in 2021: Results of the Global-PPS Project. Trop Med Infect Dis 2022; 7(5): 75.
  18. Mudenda S, Chisha P, Chabalenge B, Daka V, Mfune RL, Kasanga M, et al. Antimicrobial stewardship: knowledge, attitudes and practices regarding antimicrobial use and resistance among non-healthcare students at the University of Zambia. JAC Antimicrob Resist 2023; 5(6): dlad116.
  19. Tiri B, Sensi E, Marsiliani V, Cantarini M, Priante G, Vernelli C, et al. Antimicrobial Stewardship Program, COVID-19, and Infection Control: Spread of Carbapenem-Resistant Klebsiella Pneumoniae Colonization in ICU COVID-19 Patients. What Did Not Work? J Clin Med 2020; 9(9): 2744.
Journal of Isfahan Medical School
Volume 43, Issue 835
3rd Week,, December
November and December 2026
Pages 1328-1336

Files

History

  • Receive Date: 24 January 2025
  • Accept Date: 28 December 2025

Share

How to cite

Statistics